Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
24.12
+0.52 (2.20%)
At close: Mar 4, 2026, 4:00 PM EST
24.12
0.00 (0.00%)
After-hours: Mar 4, 2026, 4:43 PM EST
Arcutis Biotherapeutics Revenue
In the year 2025, Arcutis Biotherapeutics had annual revenue of $376.07M with 91.34% growth. Arcutis Biotherapeutics had revenue of $129.50M in the quarter ending December 31, 2025, with 81.48% growth.
Revenue (ttm)
$376.07M
Revenue Growth
+91.34%
P/S Ratio
8.03
Revenue / Employee
$1,062,350
Employees
354
Market Cap
2.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.07M | 179.53M | 91.34% |
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 588.99M |
| Tarsus Pharmaceuticals | 451.36M |
| Arcus Biosciences | 247.00M |
| IDEAYA Biosciences | 218.71M |
| Beam Therapeutics | 139.74M |
| Viridian Therapeutics | 70.85M |
| Liquidia | 69.22M |
ARQT News
- 1 day ago - Baron Health Care Fund Q4 2025 Recent Activity - Seeking Alpha
- 1 day ago - Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - GlobeNewsWire
- 5 days ago - Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference - GlobeNewsWire
- 6 days ago - Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case - Seeking Alpha
- 6 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments - GlobeNewsWire
- 12 days ago - Arcutis After The Double: Hypergrowth Peaks, Compounding Remains - Seeking Alpha